- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05545007
Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases (SUPPORT)
Phase III Randomized Trial Comparing Preoperative Hypofractionated Radiosurgery (HSRS) to Postoperative Hypofractionated Radiosurgery (HSRS) for Patients With Large Brain Metastases (= 2.1cm) Suitable for Surgical Resection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The occurrence of BMs is a huge and challenging issue affecting about 20-40% of patients with solid primary tumors. Among these, about 25% of patients harbored large BMs, defined as ≥ 2.1 cm. Single dose SRS, using the dose guidelines suggested by the Radiation Therapy Oncology Group (RTOG) 90-05 study, obtains an unsatisfactory local control (LC) rate ranging from 45-49%. In this subset of patients other treatment pathways have been investigated. In the 1990s, Patchell and colleagues determined that patients with good functional status, and solitary intracranial metastases should undergo surgical resection. Unfortunately, surgery alone is able to control tumor in only 50% of patients, and an adjuvant radiation therapy (RT) is required. For several years, adjuvant whole brain radiation therapy (WBRT) has been considered the standard of cure, but a high risk of impairment in neurological functions was recorded, without an actual benefit on survival. Different RT approaches have been inquired with the aim to reduce neurological toxicity preserving the same brain tumor control. Recent randomized trials showed that single dose SRS on the tumor bed might be a valid, and less toxic alternative to WBRT, although an increased risk of radio necrosis (RN) was noticed when large surgical cavities are treated. In the last years hypofractionated stereotactic radiosurgery (HSRS) has gained interest. Its goal is to reduce the risk of RN compared to single dose SRS, while providing similar, or perhaps, improved LC, probably in relation to the need of reducing the dose prescribed in cases of larger lesions using SRS.
However, there has been increasing evidence that patients treated with postoperative SRS have an increased rates of leptomeningeal disease (LMD) occurrence than what was observed when postoperative WBRT was used as the standard. Several retrospective studies have demonstrated a LMD rates up to 31% in the postoperative SRS setting.
The proposed mechanism of this increased risk is iatrogenic tumor dissemination into the cerebrospinal fluid (CSF) at the time of surgical resection, which was not as apparent when the entire intracranial CSF space was treated with routine postoperative WBRT, but has become more apparent with increasing use of postoperative SRS only. It is important to note that a standardized definition of radiographic LMD does not exist and ascertainment bias as to what constitutes radiographic LMD (vs local or distant meningeal failure as an example) is an unresolved issue.
Due to the perceived drawbacks of postoperative SRS, namely the need for cavity margin expansion due to target delineation uncertainty, the variable postoperative clinical course and potential delay in administering postoperative SRS, and the theoretical risk of tumor spillage into CSF at the time of surgery, investigators began to study the use of preoperative SRS as an alternative paradigm to maximize local control of the resection cavity and minimize neurocognitive detriment associated with WBRT. Preoperative SRS has several potential advantages compared to postoperative SRS consisting in :
- a better target delineation to an intact lesion
- the reduction of normal brain irradiated considering the useless of additional margins
- the potential prevention of any cells spilled during resection
- a greater oxygenation ratio of the intact region
- a sterilization effect
- the resection of the majority of irradiated tissues Based on this background we designed this phase III randomized trial comparing preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pierina Navarria, MD
- Phone Number: +39 028224 7458
- Email: pierina.navarria@cancercenter.humanitas.it
Study Contact Backup
- Name: Federico Pessina, MD
- Phone Number: +39 028224 4617
- Email: federico.pessina@hunimed.eu
Study Locations
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Recruiting
- Irccs Istituto Clinico Humanitas
-
Contact:
- Pierina Navarria, MD
- Phone Number: 0282247458
- Email: pierina.navarria@humanitas.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >18 years
- Histological or cytological confirmation of solid tumor malignancy
- Clinical indication for surgical resection of one brain metastasis
- Karnosky performance status (KPS) ≥70
- Controlled or responsive extra cranial metastatic lesions
- Limited brain metastases (1-4 BMs)
- Single metastatic lesion ≥ 2.1 cm in maximum diameter (4 cm3)
- Lesions ≤2 cm conditioning mass effect or neurological deficits or massive edema unresponsive to steroids
- Written informed consent form
Exclusion Criteria:
- Prior WBRT
- KPS < 70
- Diagnosis of small cell lung cancer (SCLC), germinal cell tumour or Lymphoproliferative disease
- Pregnant women
- Prior open neurosurgery for malignancy
- More than 4 brain metastases
- Patients with incompatibility to perform MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSRS pre-operative
Patients undergo HSRS (hypofractionated Radiosurgery) on day 1, consisting in 27 Gray (gy) administered in 3 daily fractions. Within 1 weeks, patients undergo surgical resection. |
HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
Complete surgical resection of brain lesions with adeguate margins.
|
Active Comparator: HSRS post-operative
Patients undergo surgical resection on day 1.
Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.
|
HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
Complete surgical resection of brain lesions with adeguate margins.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of LMD (leptomeningeal disease) occurrence
Time Frame: 1 year
|
Rate of LMD occurrence in patients who receive HSRS prior to surgery as compared to patients who receive HSRS after surgery.
This assessment will be evaluated through radiological images.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of local recurrence
Time Frame: 1 year
|
To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of local recurrence.
This assessment will be evaluated through radiological images.
|
1 year
|
Rate of brain distant progression
Time Frame: 1 year
|
To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of brain distant progression.
This assessment will be evaluated through radiological images.
|
1 year
|
Overall Survival
Time Frame: 1 year
|
To evaluate for patients with brain metastases whether there is improved overall survival for patients who receive HSRS prior to surgery as compared to patients who receive HSRS after surgery.
|
1 year
|
Radiation Necrosis Evaluation
Time Frame: 1 year
|
To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of symptomatic radiation necrosis (RN).
RN will be evaluated through radiological images.
|
1 year
|
Rate of surgical Morbidity
Time Frame: 1 year
|
To evaluate whether preoperative SRS increases rates of surgical morbidity including postoperative complications such as wound infection, need for longer hospital stays, readmission and eventual delay of systemic treatments
|
1 year
|
Quality of Life and neurocognitive functions evaluation
Time Frame: 1 year
|
To evaluate quality of life (EORTC QLQ-C30, version 3.0) and neurocognitive functions throught specific questionnaires administered to patients. Neurocognitive test:
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3270
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases, Adult
-
UMC UtrechtRecruitingBrain Metastases, Adult | Brain Neoplasms, Adult, MalignantNetherlands
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Duke UniversityVarian Medical SystemsCompleted
-
University of Vermont Medical CenterRecruiting
-
University Hospital, BrestRecruiting
Clinical Trials on Hypofractionated Radiosurgery (HSRS)
-
University Hospital Schleswig-HolsteinUniversity of Luebeck; Saphir Radiosurgery Center Northern GermanyActive, not recruitingProstate CancerGermany
-
University Hospital Schleswig-HolsteinUniversity of Luebeck; Saphir Radiosurgery Center Northern GermanyCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic Malignant Neoplasm to BrainUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteRecruiting
-
Huashan HospitalActive, not recruiting
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
Centre Francois BaclesseAssociation de Neuro-Oncologues d'Expression FrancaiseActive, not recruitingBrain Metastasis | OligoprogressionFrance
-
Technical University of MunichRecruitingBrain Metastases | Resection CavityGermany
-
Stanford UniversityCompletedGlioblastoma | Glioblastoma Multiforme | Cancer of Brain and Nervous SystemUnited States
-
Medical University InnsbruckRecruiting